Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
for Prostate Cancer (Adenocarcinoma)
8 locations incl. La Jolla
Sponsor: Acerand Therapeutics (Hong Kong) Limited
Sex: Male·Age: 18+
Code: NCT06801236·Phase 1·Recruiting